Vasopressin for Vasoplegic Shock Market Size, Share & COVID-19 Impact Analysis, By Application (Sepsis, Post Cardiac Surgery, and Others) Regional Forecast, 2020-2027

The global vasopressin for vasoplegic shock market size was USD 890.9 million in 2019 and is projected to reach USD 2,657.9 million by 2027, exhibiting a CAGR of 14.8% during the forecast period.

Vasopressin is an antidiuretic hormone directed to be used for the treatment and prevention of postoperative abdominal distention in abdominal roentgenography. It is mostly used as an intensive care medicine. Vasopressin infusion efficiently increases systemic vascular resistance and arterial pressure while improving survival chances in patients. Additionally, it decreases catecholamine vasopressors requirements in the patient with or at the risk of vasoplegic syndrome after cardiac surgery. The growing number of cardiac surgeries across the globe is one of the major factors boosting demand for these drugs during the forecast period. Moreover, the increasing prevalence of sepsis disorder worldwide is another important factor propelling the market during the forecast timeframe.

Additionally, the increasing number of pilot programs, and double blind randomized clinical trials evaluating the efficacy of vasopressin for vasodilatory shock and also for the analysis of treatment accessibility for cardiogenic shock among the population is one of the strong factors augmenting the market expansion.

Growing Risk of Cardiac Syndromes in COVID-19 Patients is Anticipated to Boost Product Sales

The COVID-19 outbreak has had a positive impact on the vasopressin for vasoplegic shock market. The significant increase in the number of COVID-19 cases across the globe has spiked the demand for these drugs. This is due to the fact that patients infected with the SARS-Covid-19 virus are at major risk of developing or recurring cardiac syndromes. Hence, the aforementioned factor has influenced the pharmaceutical industry to focus on the supply and development of vasopressin drugs for the treatment of such cases.

The maximum COVID-19 cases admitted to the intensive care unit are due to severe lung ailments requiring invasive mechanical ventilation and those suffering from acute respiratory distress syndrome. Acute respiratory distress syndrome (ARDS) is associated with a higher incidence of pulmonary arterial hypertension. These factors might lead to septic shock, which is a life-threatening complication in COVID-19 patients. The number of cardiac surgeries has declined in the first and second quarter of 2020 due to the COVID-19 impact. However, the emphasis on the issues related to the recurrence of cardiac syndromes and sepsis in the COVID-19 patients have influenced the major manufacturers to continue their production and distribution without any obstacle. Owing to the aforementioned factors, the use of arginine vasopressin in the treatment of COVID-19 in septic shock has now been included in national and international guidelines. Also, in April 2020, AMOMED Pharma announced the development of vasopressin drugs for patients suffering from septic shock at the intensive care units.

Many companies are maintaining key inventory at major distribution centers away from high-risk areas and working with external suppliers to maintain the continuity of the company's supply chain during the pandemic.

LATEST TRENDS

Request a Free sample to learn more about this report.

Personalized Approach for Multimodal Treatment is the New Therapeutic Approach

Vasoplegia is a ubiquitous phenomenon in all advanced shock states, including cardiogenic, septic, anaphylactic, and distributive shock. Its pathophysiology is intricate, including various mechanisms in vascular smooth muscle cells such as G protein-coupled receptor desensitization. A better understanding of these procedures is gradually changing the basic therapeutic approach to vasoplegic shock from a standardized to a personalized multimodal treatment with the prescription of several vasopressors. Moreover, growing number of double blind, randomized clinical studies pertaining to evaluate the efficacy of vasopressin for critically ill patients, and for patients with septic shock will further strengthen market growth. 

The most recent Surviving Sepsis Campaign guidelines stated that the most optimal therapeutic treatment of vasoplegic shock could be a combination of multiple vasopressors, including an early prescription of vasopressin, coupled with norepinephrine infusion in patients. Hence, based on new pathophysiological data, two novel potential drugs, angiotensin II and selepressin, are currently being evaluated.

DRIVING FACTORS

Increasing Number of Cardiovascular Surgeries to Drive the Market Demand

There has been a significant increase in the number of cardiac surgeries across the globe, and most of it requires vasopressin to control the flow of blood as well as to prevent the patient from undergoing sepsis. For instance, in 2018, according to a new study published by the Centers for Disease Control and Prevention (CDC), approximately 340,000 Coronary Artery Bypass Grafting (CABG) procedures are performed in the U.S. every year. A CABG procedure is a common cardiac surgery where a harvested vein is grafted onto the heart to bypass blocked arteries. Such surgeries have a high risk of vasoplegic shock, and the growing number of CABG procedures will strongly augment the market of vasopressin for vasoplegic shock.  

Rising Prevalence of Sepsis to Surge Demand for Vasopressin

The growing prevalence of sepsis worldwide is one of the major factors stimulating vasopressin for vasoplegic shock market growth during the forecast period. High incidence of sepsis cases across the developed and developing economies have surged demand for vasopressin drugs. For instance, as per the CDC report 2018, around 1.7 million adults in the U.S. are suffering from sepsis. In addition to this, nearly 270,000 Americans die as a result of sepsis.

RESTRAINING FACTORS

Side Effect of Vasopressin Might Restrict Market Growth

Despite its benefits in treating vasoplegic shock, the usage of vasopressin reflects various side effects, which might act as a restraining factor for the market. For instance, vasopressin doses higher than 0.04U/min are not associated with increased effectiveness but with more side effects. Moreover, high dose of vasopressin might result in severe conditions.

SEGMENTATION

By Application Analysis

To know how our report can help streamline your business, Speak to Analyst

Sepsis Segment to Hold the Significant Share of the Global Market

Based on application, the market of vasopressin for vasoplegic shock is segmented into sepsis, post-cardiac surgery, and others.

The sepsis segment holds a major share of the market and is anticipated to grow at a significant rate in the forthcoming years. This is due to the increasing prevalence and diagnosis of sepsis across the globe. For instance, as per the National Institute for Health and Care Excellence (NICE), it is estimated that there are around 123,000 cases of sepsis in England every year, resulting in around 36,900 deaths.

The tremendous rise in the number of cardiac surgeries, along with the introduction of new treatment models for vasopressin shock through extensive research, is leading to the accelerated growth of the post-cardiac surgery segment.

REGIONAL INSIGHTS

To get more information on the regional analysis of this market, Request a Free sample

The vasopressin for vasoplegic shock market size in North America stood at USD 561.3 million in 2019. The increasing prevalence of sepsis across the region, coupled with the growing numbers of cardiac surgeries, is the major factor augmenting market growth during the forecast period. Moreover, vasostrict is the only FDA-approved injection product, which aids in increasing the blood pressure in adults with vasodilatory shock, who remain hypotensive despite catecholamines and fluids.

The market in Europe is likely to experience significant growth. This is attributable to the strong government investments to strengthen the R&D sector to develop highly advanced treatment modules for vasoplegic shock. Additionally, key players in the region are strongly focusing on the launch of novel therapeutics for the treatment of vasoplegia. For instance, in April 2020, AMOMED Pharma announced the launch of novel arginine-vasopressin for catecholamine refractory hypotension in septic shock among COVID 19 patients.

Asia Pacific market of vasopressin for vasoplegic shock is anticipated to showcase considerable growth during the forecast period owing to the increasing number of manufacturers penetrating the uncharted economies in the region.

Latin America is anticipated to showcase substantial growth during the forecast period owing to the increasing number of major players penetrating the untrodden market in Latin America.

The Middle East and Africa is anticipated to hold a considerable portion of the market in terms of revenue during the forecast period. This is due to the increasing prevalence of heart disorders across the region.

KEY INDUSTRY PLAYERS

Robust presence in the U.S. Market has supported Endo International Plc. to maintain its Market Dominance

The global market of vasopressin for vasoplegic shock is consolidated by the presence of Endo International Plc., AMOMED Pharma, and others that are the leading players in the market. A diversified product portfolio, strong geographical presence, and robust research & development domain are some of the factors responsible for the well-built position of these companies in the market.

LIST OF KEY COMPANIES PROFILED:

• Endo International plc (Dublin, Ireland)


• AMOMED Pharma (Vienna, Austria)


• La Jolla Pharmaceutical Company (California, U.S.)


• Pfizer Inc. (New York, U.S.)


• Ferring Pharmaceuticals (Saint-Prex, Switzerland)


• Fresenius Kabi Canada (Toronto, Canada)


• Astellas Pharma (Tokyo, Japan)


• Eagle Pharmaceuticals, Inc. (New Jersey, U.S.)


• Others

KEY INDUSTRY DEVELOPMENTS:

• April 2020 – AMOMED Pharma announced the development of arginine vasopressin injection for the treatment of septic shock in patients infected with COVID-19.


• April 2018 - Eagle Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its abbreviated new drug application (ANDA) for vasopressin injection, 1ml. This product is the generic version of Endo International plc’s original Vasostrict formulation, which is indicated to increase blood pressure in adults with vasodilatory shock.

REPORT COVERAGE

To gain extensive insights into the market, Request for Customization

The report provides a detailed analysis of the market and focuses on crucial aspects such as leading companies, products in the pipeline, recent key industry developments, and therapeutic advancements. Also, the report offers insights into market trends and highlights vital industry developments. In addition to the factors mentioned above, the report encompasses various factors that have contributed to the growth of the market over recent years.

Report Scope & Segmentation